Annovis Bio (FRA:07X) Tariff Resilience Score: 6/10 (As of Jul. 09, 2026)


FRA:07X Annovis Bio Inc FRA:07X
32 GF Score
Price €1.72
! 1 Warning Sign
View Full Analysis

What is Annovis Bio Tariff Resilience Score?

Annovis Bio FRA:07X +2.14% 32 Tariff Resilience Score is 6 as of Jul. 09, 2026. GuruFocus rates FRA:07X with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,368 Biotechnology companies, Annovis Bio ranks better than 75.95% on this metric.

Annovis Bio has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Annovis Bio has Biotech firm with moderate exposure to tariffs on imported raw materials. Historical impacts have been limited, and potential for alternative suppliers exists. Pricing power is moderate.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Annovis Bio might have Average Resilient.

Annovis Bio  (FRA:07X) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Annovis Bio Tariff Resilience Score Related Terms

FRA:07X vs HYFT, EXOZ, ACRV: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Annovis Bio's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annovis Bio Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annovis Bio's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Annovis Bio's Tariff Resilience Score falls into.


FRA:07X
32GF Score
Annovis Bio Inc FRA:07X
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Annovis Bio (FRA:07X) has a Tariff Resilience Score of 6 as of Jul. 09, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Annovis Bio ranks #329 out of 1368 companies in the Biotechnology industry, placing it in the top 24%.
Is Annovis Bio's Tariff Resilience Score too high?
Annovis Bio's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Annovis Bio's value of 6 is 50% above this industry median. Based on the distribution chart, Annovis Bio ranks #329 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Annovis Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Annovis Bio's Tariff Resilience Score compare to HYFT and EXOZ?
According to the Biotechnology industry distribution chart, Annovis Bio ranks #329 out of 1368 companies for Tariff Resilience Score. This places Annovis Bio in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Annovis Bio's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Annovis Bio's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annovis Bio's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annovis Bio stock overvalued right now?
Annovis Bio (FRA:07X) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Annovis Bio's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Annovis Bio (FRA:07X), the current Tariff Resilience Score is 6 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annovis Bio Business Description

Other Exchanges ANVS:USA
Address 101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
32GF Score

Get the complete analysis for FRA:07X

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.72
Price